Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3-phosphoinositide-dependent protein kinase 1 (PDK1) pleckstrin homology (PH) domain is a critical regulatory module located at the C-terminus of the PDK1 enzyme, which is often described as a master kinase due to its role in activating numerous AGC family kinases. This domain specifically binds to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) at the plasma membrane, a process essential for the recruitment and subsequent activation of Akt (protein kinase B) via phosphorylation at Thr308. While the PDK1 kinase domain can activate other substrates like S6K and SGK in the cytosol through the PIF pocket, the PH domain is uniquely required for the membrane-dependent activation of the Akt signaling axis. Consequently, the PDK1 PH domain has emerged as a high-value therapeutic target for allosteric inhibitors designed to selectively disrupt Akt signaling—which is frequently hyperactivated in various cancers—without interfering with other vital PDK1-dependent pathways. Targeting this domain offers a potential advantage over traditional ATP-competitive inhibitors by providing greater pathway selectivity, although therapeutic challenges include managing potential metabolic side effects such as insulin resistance and growth impairment.
Allosteric inhibition of PDK1 recruitment to the plasma membrane by blocking the interaction between the PH domain and phosphoinositides (PIP3/PI(3,4)P2), thereby preventing the co-localization and activation of Akt (protein kinase B) via Thr308 phosphorylation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-phosphoinositide-dependent protein kinase 1 (PDK1) pleckstrin homology domain (PDK1 PH domain).